Generic Medicine Info
Indications and Dosage
Abdominal infections, Abscess of liver, Cholecystitis, Cystitis, Endometriosis, Intra-abdominal infections, Lung abscess, Peritonitis, Pneumonia, Prostatitis, Pyelonephritis, Secondary infections in trauma, burns, or surgical wounds
Adult: 500 mg via infusion over 30-60 minutes bid. May reduce dose to 300 mg bid depending on age, symptoms and severity of infection. Max duration of therapy: 14 days.
Renal Impairment
Moderate to severe: 300 mg bid.
Hypersensitivity. Pregnancy.
Special Precautions
Patient with convulsive disorder, epilepsy. Moderate to severe renal impairment.
Adverse Reactions
Significant: Hypersensitivity reactions.
Gastrointestinal disorder: Diarrhoea, nausea, vomiting.
General disorders and administration site conditions: Inj site reactions (e.g. pain, erythema, swelling, induration, phlebitis).
Nervous system disorders: Rarely, convulsion.
Skin and subcutaneous tissue disorders: Rashes.
Mechanism of Action: Pazufloxacin is a fluoroquinolone antibacterial. It exerts its bactericidal activity by inhibiting both DNA gyrase and topoisomerase IV enzyme leading to increased antibacterial spectrum.
Absorption: Time to peak plasma concentration: 30 minutes.
Distribution: Widely distributed throughout the body (e.g. phlegm, lungs, biliary tract, pleural fluid, genital organs, CSF).
Excretion: Via urine (89.5-93.8%, as unchanged drug). Terminal elimination half-life: 1.65-1.88 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Pazufloxacin, CID=65957, (accessed on Jan. 22, 2020)

MIMS Class
ATC Classification
J01MA18 - pazufloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Buckingham R (ed). Pazufloxacin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 08/05/2018.

Disclaimer: This information is independently developed by MIMS based on Pazufloxacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in